(112 days)
The Microlife Upper Arm Automatic Dizital Blood Pressure Monitor. Model BP3MW1-4B is a device intended to measure the systolic and diastolic blood pressure, pulse rate of an adult individual by using a non-invasive oscillometric technique in one inflatable cuff is wrapped around the single upper arm.
The device detects the appearance of irregular heartbeat during measurement, and gives a warning signal with the reading once the irregular heartbeat is detected.
This device can accurately measure blood pressure in pregnant patients including those with known or suspected preeclampsia.
The memory data can be transferred to the PC (personal computer) running the Microlife Blood Pressure Analyzer (BPA) software by connecting the monitor via cable. The device can also be used in connection with smart mobile devices running the APP and via Bluetooth.
The blood pressure monitor is a fully automatic digital blood pressure measuring device for use by adults on the upper arm at home.
Microlife Upper Arm Automatic Digital Blood Pressure Monitor, Model BP3MW 1-4B is designed to measure systolic and diastolic blood pressure, pulse rate of an individual by using a non-invasive technique in which one inflatable cuff is wrapped around the single upper arm. Our method to define systolic and diastolic pressure is similar to the auscultatory method but use two resistive pressure sensors rather than a stethoscope and mercury manometer. The sensors convert tiny alterations in cuff pressure to electrical signals, by analyzing those signals to define the systolic and diastolic blood pressure and calculating pulse rate, which is a well - known technique in the market called the "oscillometric method". This device can accurately measure blood pressure in pregnant patients including those with known or suspected preeclampsia.
The device detects the appearance of irreqular heartbeat during measurement. and the symbol " memory data can be transferred to the PC (personal computer) running the Microlife Blood Pressure Analyzer (BPA) software by connecting the monitor via cable. The device can also be used in connection with smart mobile devices running the APP and via Bluetooth.
The provided text is a 510(k) Summary for the Microlife Upper Arm Automatic Digital Blood Pressure Monitor, Model BP3MW1-4B. It primarily describes how the new device is substantially equivalent to previously cleared predicate devices. While it mentions clinical validation and standards, it explicitly states that new clinical testing for the subject device was not performed because it is technically identical to a predicate device regarding the measurement algorithm and program codes. Therefore, the details requested about acceptance criteria and a new study done to prove the device meets these criteria are largely absent for this specific device model.
However, I can extract information related to the predicate device's clinical validation as that is what the new device is inheriting its performance claims from.
Here's a breakdown of the available information based on your requested points:
Acceptance Criteria and Device Performance
The document does not explicitly present a table of acceptance criteria and reported device performance for the specific device in question (BP3MW1-4B). It states that the device's performance is identical to its predicate device, BP3MW1-4X(R), due to identical technical specifications, measurement algorithm, and program codes.
Therefore, the acceptance criteria and performance would be those established for the predicate device, which would have been validated against standards such as ANSI/AAMI IEC81060-2: "Non-invasive sphygmomanometers – Part 2: Clinical validation of automated measurement type." This standard sets criteria for accuracy in blood pressure measurements.
Based on the reference to ANSI/AAMI IEC81060-2 in the text, typical acceptance criteria for blood pressure monitors would involve:
- Mean Difference (Bias): The average difference between the device's readings and reference measurements (e.g., auscultatory readings).
- Standard Deviation (Precision): The variability of the device's readings compared to reference measurements.
- Number of readings within certain absolute differences: For example, how many readings are within ±5 mmHg, ±10 mmHg, etc.
As the document explicitly states "Repeat clinical testing in accordance with the standard ANSI/AAMI IEC81060-2 for the subject device BP3MW1-4B is therefore not necessary," it does not provide a new table of acceptance criteria and reported performance for this specific model.
Study Information (Inherited from Predicate Device)
Given that the clinical performance is inherited from the predicate device BP3MW1-4X(R), the following points relate to the type of study that would have been performed for that predicate device to meet the ANSI/AAMI IEC81060-2 standard, which is referenced. The document for K153077 does not provide the specific details for that predicate device's study.
-
Sample size used for the test set and the data provenance:
- Sample Size: Not specified in this 510(k) summary for the predicate device's clinical validation. The ANSI/AAMI IEC81060-2 standard typically requires a minimum of 85 participants for clinical validation.
- Data Provenance: Not specified. Clinical validation studies for such devices are typically prospective, conducted in a clinical setting.
-
Number of experts used to establish the ground truth for the test set and the qualifications of those experts:
- Number of Experts: Not specified. For blood pressure monitor validation studies (e.g., against ANSI/AAMI IEC81060-2), at least two trained observers (e.g., physicians or nurses) are typically used for reference auscultatory measurements.
- Qualifications: "Trained observers" who are specifically skilled in auscultatory blood pressure measurement.
-
Adjudication method for the test set:
- Adjudication Method: Not explicitly stated. In blood pressure validation studies using multiple observers, differences between the observers' readings are typically handled by averaging the readings if they are within a specified tolerance, or by discarding the measurement if they are outside a tolerance, or by having a third observer adjudicate.
-
If a multi reader multi case (MRMC) comparative effectiveness study was done:
- MRMC Study: No. This type of study (MRMC) is generally for diagnostic imaging devices assessing reader performance. Blood pressure monitor validation primarily focuses on the device's accuracy in comparison to a reference standard, not on human reader improvement with AI assistance.
-
If a standalone (i.e. algorithm only without human-in-the-loop performance) was done:
- Standalone Performance: Yes, the clinical validation is a standalone performance assessment of the oscillometric algorithm against the auscultatory reference. The "algorithm only" aspect is inherent in the device's automated function.
-
The type of ground truth used:
- Ground Truth: Expert consensus auscultatory readings obtained concurrently by trained observers using a mercury sphygmomanometer or validated equivalent are the standard ground truth for blood pressure monitor validation according to ANSI/AAMI IEC81060-2.
-
The sample size for the training set:
- Training Set Sample Size: Not specified. Blood pressure monitor algorithms are typically developed using internal datasets, and the clinical validation (as discussed above) is usually a separate external validation.
-
How the ground truth for the training set was established:
- Training Set Ground Truth: Not specified in this document. During algorithm development, it would likely involve carefully measured blood pressure data (potentially also using auscultatory reference) from a diverse population to train and optimize the oscillometric algorithm.
{0}------------------------------------------------
Image /page/0/Picture/0 description: The image shows the logo for the U.S. Department of Health & Human Services. The logo consists of a circular seal with the text "DEPARTMENT OF HEALTH & HUMAN SERVICES - USA" around the perimeter. Inside the circle is an abstract symbol resembling three human profiles facing right, stacked on top of each other.
DEPARTMENT OF HEALTH & HUMAN SERVICES
Public Health Service
Food and Drug Administration 10903 New Hampshire Avenue Document Control Center - WO66-G609 Silver Spring, MD 20993-0002
February 12, 2016
Microlife Intellectual Property Gmbh % Susan Goldstein-Falk Official Correspondent For Microlife Intellectual Property Gmbh Mdi Consultants, Inc. 55 Northern Blvd., Suite 200 Great Neck, New York 11021
Re: K153077
Trade/Device Name: Microlife Upper Arm Automatic Digital Blood Pressure Monitor, Model BP3MW1-4B Regulation Number: 21 CFR 870.1130 Regulation Name: Noninvasive Blood Pressure Measurement System Regulatory Class: Class II Product Code: DXN Dated: January 11, 2016 Received: January 13, 2016
Dear Susan Goldstein-Falk:
We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration. Please note: CDRH does not evaluate information related to contract liability warranties. We remind you, however, that device labeling must be truthful and not misleading.
If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.
Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply
{1}------------------------------------------------
with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); medical device reporting of medical devicerelated adverse events) (21 CFR 803); good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820); and if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050.
If you desire specific advice for your device on our labeling regulation (21 CFR Part 801), please contact the Division of Industry and Consumer Education at its toll-free number (800) 638-2041 or (301) 796-7100 or at its Internet address
http://www.fda.gov/MedicalDevices/ResourcesforYou/Industry/default.htm. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21 CFR Part 807.97). For questions regarding the reporting of adverse events under the MDR regulation (21 CFR Part 803), please go to
http://www.fda.gov/MedicalDevices/Safety/ReportaProblem/default.htm for the CDRH's Office of Surveillance and Biometrics/Division of Postmarket Surveillance.
You may obtain other general information on your responsibilities under the Act from the Division of Industry and Consumer Education at its toll-free number (800) 638-2041 or (301) 796-7100 or at its Internet address
http://www.fda.gov/MedicalDevices/ResourcesforYou/Industry/default.htm.
Sincerely vours.
Mitchell Stein
forBram D. Zuckerman, M.D. Director Division of Cardiovascular Devices Office of Device Evaluation Center for Devices and Radiological Health
Enclosure
{2}------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES Food and Drug Administration
Indications for Use
510(k) Number (if known) K153077
Device Name
Microlife Upper Arm Automatic Digital Blood Pressure Monitor, Model BP3MW1-4B
Indications for Use (Describe)
The Microlife Upper Arm Automatic Dizital Blood Pressure Monitor. Model BP3MW1-4B is a device intended to measure the systolic and diastolic blood pressure, pulse rate of an adult individual by using a non-invasive oscillometric technique in one inflatable cuff is wrapped around the single upper arm.
The device detects the appearance of irregular heartbeat during measurement, and gives a warning signal with the reading once the irregular heartbeat is detected.
This device can accurately measure blood pressure in pregnant patients including those with known or suspected preeclampsia.
The memory data can be transferred to the PC (personal computer) running the Microlife Blood Pressure Analyzer (BPA) software by connecting the monitor via cable. The device can also be used in connection with smart mobile devices running the APP and via Bluetooth.
The blood pressure monitor is a fully automatic digital blood pressure measuring device for use by adults on the upper arm at home.
| Type of Use (Select one or both, as applicable) | |
|---|---|
| ------------------------------------------------- | -- |
Prescription Use (Part 21 CFR 801 Subpart D)
Over-The-Counter Use (21 CFR 801 Subpart C)
CONTINUE ON A SEPARATE PAGE IF NEEDED.
This section applies only to requirements of the Paperwork Reduction Act of 1995.
DO NOT SEND YOUR COMPLETED FORM TO THE PRA STAFF EMAIL ADDRESS BELOW.
The burden time for this collection of information is estimated to average 79 hours per response, including the time to review instructions, search existing data sources, gather and maintain the data needed and complete and review the collection of information. Send comments regarding this burden estimate or any other aspect of this information collection, including suggestions for reducing this burden, to:
Department of Health and Human Services Food and Drug Administration Office of Chief Information Officer Paperwork Reduction Act (PRA) Staff PRAStaff(@fda.hhs.gov
"An agency may not conduct or sponsor, and a person is not required to respond to, a collection of information unless it displays a currently valid OMB number."
Form Approved: OMB No. 0910-0120 Expiration Date: January 31, 2017 See PRA Statement below.
{3}------------------------------------------------
510(k) SUMMARY
The assigned 5l0(k) number is: K153077
1. Submitter's Identification:
Microlife Intellectual Property GmbH, Switzerland Espenstrasse 139 9443 Widnau / Switzerland
Date Summary Prepared: February 12, 2016
Contact: Mr. Gerhard Frick Vice President of Technical and Service Microlife Intellectual Property GmbH, Switzerland Tel: +41 79 216 0070 E-Mail: gerhard.frick@microlife.ch
2. Name of the Device:
Microlife Upper Arm Automatic Digital Blood Pressure Monitor, Model BP3MW1-4B
Regulation Number: 21 CFR Part 870.1130 Regulation Name: Non-Invasive Blood Pressure Measurement System Regulatory Class: II Product Code: DXN
Information for the 510(k) Cleared Device (Predicate Device): 3.
- a. Microlife Upper Arm Automatic Digital Blood Pressure Monitor, Model BP3MW1-4X(R), K140572, Microlife Intellectual Property GmbH.
- b. Microlife Upper Arm Automatic Digital Blood Pressure Monitor, Model BP3NF1-2B, K151869, Microlife Intellectual Property GmbH.
Device Description: 4.
Microlife Upper Arm Automatic Digital Blood Pressure Monitor, Model BP3MW 1-4B is designed to measure systolic and diastolic blood pressure, pulse rate of an individual by using a non-invasive technique in which one inflatable cuff is wrapped around the single upper arm. Our method to define systolic and diastolic pressure is similar to the auscultatory method but use two resistive pressure
{4}------------------------------------------------
sensors rather than a stethoscope and mercury manometer. The sensors convert tiny alterations in cuff pressure to electrical signals, by analyzing those signals to define the systolic and diastolic blood pressure and calculating pulse rate, which is a well - known technique in the market called the "oscillometric method". This device can accurately measure blood pressure in pregnant patients including those with known or suspected preeclampsia.
The device detects the appearance of irreqular heartbeat during measurement.
and the symbol " memory data can be transferred to the PC (personal computer) running the Microlife Blood Pressure Analyzer (BPA) software by connecting the monitor via cable. The device can also be used in connection with smart mobile devices running the APP and via Bluetooth.
The patient's level of blood pressure is determined in the circulatory center of the brain and adjusts to a variety of situations through feedback from the nervous system. To adjust blood pressure, the strength and frequency of the heart (pulse), as well as the width of circulatory blood vessels is altered. Blood vessel width is affected by fine muscles in he blood vessel walls.
The patient's level of arterial blood pressure changes periodically during heart activity. During the "blood ejection" (Systole), the value is highest (systolic blood pressure value). At the end of the heart's "rest period" (Diastole), pressure is lowest (diastolic blood pressure value).Blood pressure values must lie within certain normal ranges in order to prevent particular diseases.
| Category | Systolic(mmHg) | Diastolic(mmHg) |
|---|---|---|
| Normal | <120 | and <80 |
| Pre-Hypertension | 120-139 | or 80-89 |
| Hypertension | ||
| Stage 1 Hypertension | 140-159 | or 90-99 |
| Stage 2 Hypertension | ≥160 | or ≥100 |
The following standards for assessing high blood pressure (in adults) have been established by the National Institutes of Health JNC7, 2003.
{5}------------------------------------------------
The appearance of this symbol __ indicates that certain pulse irregularities were detected during the measurement. In this case, the result may deviate from your normal basal blood pressure repeat the measurement. In most cases, this is no cause for concern. However, if the symbol appears on a regular basis (e.g., several times a week with measurements taken daily), we advise you to tell your doctor.
Image /page/5/Picture/2 description: The image shows a digital display with three numbers. The top number is 129, the middle number is 78, and the bottom number is 65. To the left of the bottom number is a symbol that looks like a heart rate monitor.
The blood pressure monitor is a fully automatic digital blood pressure measuring device for use by adults on the upper arm at home.
5. Indications for Use:
The Microlife Upper Arm Automatic Digital Blood Pressure Monitor, Model BP3MW 1-4B is a device intended to measure the systolic and diastolic blood pressure, pulse rate of an adult individual by using a non-invasive oscillometric technique in one inflatable cuff is wrapped around the single upper arm.
The device detects the appearance of irregular heartbeat during measurement, and gives a warning signal with the reading once the irregular heartbeat is detected.
This device can accurately measure blood pressure in pregnant patients including those with known or suspected preeclampsia.
The memory data can be transferred to the PC (personal computer) running the Microlife Blood Pressure Analyzer (BPA) software by connecting the monitor via cable. The device can also be used in connection with smart mobile devices running the APP and via Bluetooth.
The blood pressure monitor is a fully automatic digital blood pressure measuring device for use by adults on the upper arm at home.
6. Comparison to the 510(k) Cleared Devices (Predicate Devices):
The modified device model BP3MW1-4B uses the same oscillometric method as the predicate BP3MW1-4X(R) with the same algorithm to determine the systolic and diastolic blood pressure, pulse rate. Upper arm cuff is inflated automatically by pump, the deflation rate is controlled by factory set exhaust valve and the deflation pressures are transferred via tubing to a sensor in these two units.
They differ by Bluetooth function. The subject device BP3MW1-4B has been added the function of transferring the memory data to the smart phone via
{6}------------------------------------------------
Bluetooth. However, this function is only a way to transfer the data and will not affect the clinical accuracy.
Although the cuff used with the subject BP3MW1-4B is changed to WRS cuff, it is the same with the one cleared in BP3AP1-3E, which was proved in K111652. The other differences also do not affect the accuracy and normal use of this device based on the clinical declaration of identity and clinical testing comparing different functions.
The modified device model BP3MW1-4B uses the same oscillometric method as the predicate device BP3NF1-2B. They have the same function of transferring the memory data via Bluetooth. Based upon the aforementioned information, the two devices are substantially equivalent.
7. Discussion of Non-Clinical Tests Performed for Determination of Substantial Equivalence are as follows:
Testing information demonstrating safety and effectiveness of the Microlife Upper Arm Automatic Digital Blood Pressure Monitor, Model BP3MW1-4B in the intended environment of use is supported by testing that was conducted in accordance with the FDA November 1993 Draft "Reviewer Guidance for Premarket Notification Submissions", DCRND, which outlines Electrical, Mechanical and Environmental Performance requirements.
The following testing was conducted to prove safety and effectiveness as well as substantial equivalence to the predicate devices:
The following National and International Standards were utilized for testing the subject device:
-
- IEC 60601-1 Medical electrical equipment Part 1: General requirements for basic safety and essential performance AAMI / ANSI ES60601-1:2005/(R)2012 And A1:2012., C1:2009/(R)2012 And A2:2010/(R)2012 (MISC 002)
-
- IEC 60601-1-2 Medical electrical equipment Part 1-2: General requirements for safety and essential performance - Collateral standard: Electromagnetic compatibility 3:2007-03 (MISC 001)
-
- ISO 14971 Medical devices Application of risk management to medical
devices. 2007 ( VOL 12, 002 )
- ISO 14971 Medical devices Application of risk management to medical
-
- AAMI/ANSI/ISO 10993-1-1 Biological evaluation of medical devices Part 1: Evaluation and testing. 2010 (Biocompatibility Test Report)
-
- AAMI/ANSI/ISO 10993-5 Biological evaluation of medical devices Part 5:
{7}------------------------------------------------
Tests for In Vitro Cytotoxicity, 2009 (Biocompatibility Test Report)
- AAMI/ANSI/ISO 10993-10 Biological evaluation of medical devices – Part (Biocompatibility Test Report)
-
- Tests for Irritation and skin sensitization, 2010 (Biocompatibility Test Report)
-
- AAMI/ANSI/IEC 80601-2-30 Medical electrical equipment Part 2-30: Particular requirements for the basic safety and essential performance of automated noninvasive sphygmomanometers, 2013
-
- IEC 60601-1-11 Medical Electrical Equipment Part 1-11: General Requirements For Basic Safety And Essential Performance - Collateral Standard: Requirements For Medical Electrical Equipment And Medical Electrical Systems Used In The Home Healthcare Environment
None of the testing demonstrated any design characteristics that violated the requirements of the Reviewer Guidance or resulted in any safety hazards. It was our conclusion that Microlife Upper Arm Automatic Digital Blood Pressure Monitor, Model BP3MW1-4B tested met all relevant requirements of the aforementioned tests.
8. Discussion of Clinical Tests Performed:
Clinical validation concerning the compliance of ANSI/AAMI ISO 81060-2: The subject device Model BP3MW1-4B is from the technical point of view, identical to the predicate blood pressure monitor BP3MW1-4X(R). Moreover, the measurement algorithm and its program codes of BP3MW1-4X(R) remain unchanged. The fundamental scientific technology of the modified BP3MW1-4B device is the same as the predicate device BP3MW1-4X(R). Therefore the performance of the BP3MW1-4B in terms of blood pressure measurement would be identical with performance of the predicate device BP3MW1-4X(R). Repeat clinical testing in accordance with the standard ANSI/AAMI IEC81060-2 for the subject device BP3MW1-4B is therefore not necessary as clinical testing results were not affected by the changes to the subject modified device.
9. Software information:
Software validation was conducted in accordance with a moderate level of concern designation in accordance with the FDA November 2005 document "Guidance for the Content of Premarket Submissions for Software Contained in Medical Devices". In addition, since our device requires the use of off-the-shelf software to operate the PC-link function, we adhered to the FDA September 1999 document "Guidance for Off-The-Shelf Software Use in Medical Devices".
{8}------------------------------------------------
10. Conclusions:
Conclusions drawn from the non-clinical and clinical tests demonstrate that the subject device is as safe, effective, and performs as well as the predicate device.
§ 870.1130 Noninvasive blood pressure measurement system.
(a)
Identification. A noninvasive blood pressure measurement system is a device that provides a signal from which systolic, diastolic, mean, or any combination of the three pressures can be derived through the use of tranducers placed on the surface of the body.(b)
Classification. Class II (performance standards).